熱門資訊> 正文

Keros Therapeutics开始要约回购高达1.944亿美元的股票

2025-10-20 18:26

Keros Therapeutics (NASDAQ:KROS) has commenced a cash tender offer to repurchase up to $194.4 million of common shares, at a purchase price of $17.75 per share. The Company expects to fund the tender offer from its existing cash and cash equivalents.
The tender offer, which is a part of its previously announced $375 million capital return program, will expire at 5:00 p.m. ET on Tuesday, November 18, 2025, unless extended or earlier terminated.
KROS +3.9% premarket to $14.37
Source: Press Release

More on Keros Therapeutics

Keros Therapeutics: A Potential Dart Throw
Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path
Keros jumps on plan to return $375M in excess capital
Keros gains Orphan Drug designation for Duchenne muscular dystrophy asset
Seeking Alpha’s Quant Rating on Keros Therapeutics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。